Antoine Alam

40, Avenue Tony Garnier
Lyon, 69007, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains.

AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains.

Journal: Antibody therapeutics

Published: March 09, 2024

Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.

Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.

Journal: Cancer research communications

Published: April 07, 2022

CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.

CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.

Journal: mBio

Published: April 07, 2022

Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.

Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.

Journal: Journal of hepatology

Published: July 31, 2019

Expression of the human antimicrobial peptide β-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells.

Expression of the human antimicrobial peptide β-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells.

Journal: Scientific reports

Published: June 18, 2018

A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury.

A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury.

Journal: Brain : a journal of neurology

Published: October 28, 2015

Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells.

Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells.

Journal: Cancers

Published: November 18, 2013

SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.

SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.

Journal: Molecular cancer therapeutics

Published: May 16, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026